Summary of the technology
CSIC has developed an extracellular matrix with increased synthesis and/or deposit of collagen that is capable of regulating the differentiation of mesenchymal stem cells.
Industrial partners from the biotechnological industry are being sought to collaborate through a patent licence agreement.
Description of the technology
The use of biomaterials in regenerative medicine is an excellent therapeutic strategy for the treatment of damaged tissues or organs. Biomaterials based on the production of extracellular matrix from cell cultures have recognized advantages with respect to synthetic materials. However, the standard culture conditions do not favor the efficient production and deposition of extracellular matrix components (EMC), mainly because the dilution of the cellular microenvironment hinders the extracellular action of certain enzymes necessary for the processing of matrix components, such as the enzyme that catalyzes the conversion of procollagen into collagen, the bone morphogenetic protein type 1 (BMP1), or the one that initiates the formation of covalent crosslinks in mature collagen, lysyl oxidase (LOX). In this invention a method has been developed to promote the formation and deposition of collagen from cell cultures by adding the enzymes LOX and BMP1 to the culture medium. Using this method and through the elimination of collagen-producing cells, matrices have been generated capable of providing the necessary environment for the growth, maintenance and differentiation of mesenchymal stem cells, so this procedure constitutes a methodology of great potential for production of biomaterials in regenerative medicine.
- The method strongly increases the synthesis and/or deposition of collagen onto matrices endogenously produced by fibroblast cultures and can be potentially adapted to any other matrix-producing cell type.
- The surface onto which the ECM of this invention is deposited may be capable of adhering the cells to be cultured and capable of releasing the cells when the culture process is complete.
- The matrix surfaces produced by this protocol provide the conditions required for the growth and maintenance of mesenchymal stem cells, and have been shown to regulate the osteogenic and adipogenic differentiation of these cells.
Intellectual property status
Patent already applied for
Spanish National Research Council
Research & Technology Organization
Additional information (attached documents)
About Spanish National Research Council
Research & Technology Organization from SpainSpanish National Research Council
The Spanish National Research Council (CSIC) is the largest public institution dedicated to research in Spain and the third largest in Europe. Belonging to the Spanish Ministry of Science, Innovation and Universities through the Secretary of State for Universities, Research, Development and Innovation, its main objective is to develop and promote research that will help bring about scientific and technological progress, and it is prepared to collaborate with Spanish and foreign entities in order to achieve this aim.